Skip to content

Autologous Bone Marrow Concentration for Femoral Shaft Fracture Union

The Effect of Autologous Bone Marrow Concentration on Femoral Shaft Fracture Union

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03794622
Enrollment
60
Registered
2019-01-07
Start date
2017-06-14
Completion date
2020-12-31
Last updated
2020-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Marrow, Femoral Shaft Fracture

Keywords

Bone Marrow, Mesenchymal Stromal Cells, Femoral Shaft Fracture

Brief summary

This study aims to evaluate the effect of bone marrow concentration on union of femoral shaft fracture by comparing clinical and imaging outcomes between patients receiving Intramedullary nail fixation with intraoperative bone marrow concentration and those receiving Intramedullary nail fixation only.

Detailed description

Femoral shaft fracture is a common orthopaedic injury. Intramedullary nail is one of the standard treatments. Its primary goal is to develop an osseous bridge between adjacent motion segments to prevent motion, relieve pain, and facilitate bone union. Delayed union or nonunion is common in femoral shaft fracture. Risk factors include comminuted fracture, open fracture, smoking, diabetes and open reduction of fracture fixation. Mesenchymal stem cells are pluripotent cells that can differentiate into multiple mesenchymal tissues, including tenocytes, chondrocytes and osteoblasts, as well as being a source of multiple growth factors to establish an environment conducive to soft and hard tissue regeneration. As bone marrow concentration has high concentration of mesenchymal stem cells, some studies have shown that autologous bone marrow concentration can improve bone healing. Therefore, the goal of this study was to evaluate the effect of bone marrow concentration on union of femoral shaft fracture.

Interventions

OTHERintramedullary nail fixation with bone marrow concentration

intramedullary nail fixation with bone marrow concentration

intramedullary nail fixation only

Sponsors

Aeon Biotechnology Corporation
CollaboratorINDUSTRY
Pei-Yuan Lee, MD
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* With recent diagnosis of femoral shaft fracture * Treated with intramedullary nail fixation * With one or more risk factors of non-union: comminuted fracture, open fracture, smoking, obesity, diabetes, open reduction, * Age between 20 and 80 years

Exclusion criteria

* Old femoral shaft fracture * With concurrent major trauma, ex. intracranial hemorrhage, pneumothorax, hemothorax, internal bleeding. * With prior history of femoral surgery * With current or prior history of trauma or infection at femur * With current diagnosis of coagulopathy * With current or prior history of cancer * With current or prior history of hematological disease * Pregnancy * Patients who will not cooperate with one-year followup

Design outcomes

Primary

MeasureTime frameDescription
1-month postoperative degree of union evaluated by plain radiograph1-month postoperativeDegree of union evaluated by plain radiograph

Secondary

MeasureTime frameDescription
2-month postoperative degree of union evaluated by plain radiograph2-month postoperativeDegree of union evaluated by plain radiograph
3-month postoperative degree of union evaluated by plain radiograph3-month postoperativeDegree of union evaluated by plain radiograph
6-month postoperative degree of union evaluated by plain radiograph6-month postoperativeDegree of union evaluated by plain radiograph
12-month postoperative degree of union evaluated by plain radiograph12-month postoperativeDegree of union evaluated by plain radiograph

Countries

Taiwan

Contacts

Primary ContactHsin-Chuan Chen, MD
henang0424@gmail.com+886975611139
Backup ContactPei-Yuan Lee, MD

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026